Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junichi Asano

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Pharmaceutical Statistics|August 12, 2020
A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulationsJunichi Asano, Akihiro Hirakawa
Journal of Biopharmaceutical Statistics|March 22, 2017
Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: Application to breast cancer dataJunichi Asano, Akihiro Hirakawa
BMC Medical Research Methodology|February 28, 2023
Practical basket design for binary outcomes with control of family-wise error rateJunichi Asano, Hiroyuki Sato, Akihiro Hirakawa
Pharmaceutical Statistics|July 22, 2014
Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer dataJunichi Asano, Akihiro Hirakawa, Chikuma Hamada
Clinical and Translational Science|June 14, 2021
Assessment of the impact of Japanese-specific long-term safety data on new drug approvalShinobu Uzu, Shohko Sekine, Junichi Asano, et al.
Statistics in Medicine|January 22, 2026
Bayesian Power Prior in Platform Trials With Non-Concurrent Control for Binary Outcomes: Development and Comparative EvaluationJunichi Asano, Hiroyuki Sato, Shin Watanabe, et al.
Contemporary Clinical Trials Communications|September 6, 2018
Master protocol trials in oncology: Review and new trial designsAkihiro Hirakawa, Junichi Asano, Hiroyuki Sato, et al.
Cytotherapy|March 18, 2025
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of the first conditional and time-limited approved cellular product, HeartSheetShinichi Noda, Yoko Kobayashi, Narumi Okura, et al.
Clinical Pharmacology and Therapeutics|January 3, 2025
PMDA Perspective on Use of Real-World Data and Real-World Evidence as an External Control: Recent Examples and ConsiderationsJunichi Asano, Hiromi Sugano, Hiroyuki Murakami, et al.
Medicine|January 9, 2015
Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in JapanRyosuke Sato, Mutsuhiro Ikuma, Kazunori Takagi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Pharmaceutical Statistics|August 12, 2020
A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulationsJunichi Asano, Akihiro Hirakawa
Journal of Biopharmaceutical Statistics|March 22, 2017
Assessing the prediction accuracy of a cure model for censored survival data with long-term survivors: Application to breast cancer dataJunichi Asano, Akihiro Hirakawa
BMC Medical Research Methodology|February 28, 2023
Practical basket design for binary outcomes with control of family-wise error rateJunichi Asano, Hiroyuki Sato, Akihiro Hirakawa
Pharmaceutical Statistics|July 22, 2014
Assessing the prediction accuracy of cure in the Cox proportional hazards cure model: an application to breast cancer dataJunichi Asano, Akihiro Hirakawa, Chikuma Hamada
Clinical and Translational Science|June 14, 2021
Assessment of the impact of Japanese-specific long-term safety data on new drug approvalShinobu Uzu, Shohko Sekine, Junichi Asano, et al.
Statistics in Medicine|January 22, 2026
Bayesian Power Prior in Platform Trials With Non-Concurrent Control for Binary Outcomes: Development and Comparative EvaluationJunichi Asano, Hiroyuki Sato, Shin Watanabe, et al.
Contemporary Clinical Trials Communications|September 6, 2018
Master protocol trials in oncology: Review and new trial designsAkihiro Hirakawa, Junichi Asano, Hiroyuki Sato, et al.
Cytotherapy|March 18, 2025
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of the first conditional and time-limited approved cellular product, HeartSheetShinichi Noda, Yoko Kobayashi, Narumi Okura, et al.
Clinical Pharmacology and Therapeutics|January 3, 2025
PMDA Perspective on Use of Real-World Data and Real-World Evidence as an External Control: Recent Examples and ConsiderationsJunichi Asano, Hiromi Sugano, Hiroyuki Murakami, et al.
Medicine|January 9, 2015
Exposure of drugs for hypertension, diabetes, and autoimmune disease during pregnancy and perinatal outcomes: an investigation of the regulator in JapanRyosuke Sato, Mutsuhiro Ikuma, Kazunori Takagi, et al.
Pageof 2